Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine

Exclusion Criteria

• •Positive pregnancy test at screening or within 24 hours of study product dosing
• •Poor venous access, as defined by inability to obtain venous blood after 3 venipuncture attempts (this criterion does not apply to cohort 4)
• •Abnormal vital signs, defined as:
• •Systolic BP greater than 150 mmHg or Diastolic BP greater than 90 mmHg Resting heart rate greater than 100 Oral temperature greater than or equal to 100.4 degrees F
• •Persons with IgA deficiency (serum IgA less than 70 mg per dL
• •Serum S. flexneri 2a LPS igG titer greater than or equal to 2500
• •Received prior vaccines or had prior infection (natural or challenge) with ETEC or Shigella, within 5 years prior to enrollment
• •Symptoms of Traveler's diarrhea associated with travel to countries where Shigella or other enteric infections are endemic (most of the developing world) within 3 years prior to enrollment
• •History of chronic gastrointestinal illness, including sever dyspepsia, lactose intolerance, or other significant gastrointestinal tract disease
• •Use of antimicrobials within 2 weeks of each dose of vaccine or the challenge
• •Regular use (greater than or equal to weekly) of laxatives, anti-diarrheal agents, anti-constipation agents, or antacid therapies
• •History of major gastrointestinal surgery (uncomplicated laparoscopic appendectomy or cholecystectomy greater than 1 year prior is permitted)
• •Abnormal bowel pattern, defined by less than 3 stools per week or greater than 2 stools per day in the past 6 months
• •Use of oral, parenteral or high-dose inhaled steroids within 30 days of each dose of vaccine or the challenge
• •Use of any medication which might affect immune function within 30 days of each dose of vaccine or the challenge
• •Current medical condition which requires daily or weekly prescribed medications for control (as medication use is limited during the inpatient stay), may be an exclusion criterion if in the judgement of the investigator the potential for missed doses could represent a significant risk to the subject's health
• •History of reactive arthritis
• •Diagnosis of schizophrenia or other major psychiatric disease
• •History of seizure disorder within the last 5 years
• •History of alcohol or drug abuse within the last 5 years
• •Presence of immunosuppression
• •Known significant allergy (i.e., anaphylaxis) to ciprofloxacin, trimethoprim-sulfamethoxazole (Bactrim), or a tetanus-containing vaccine
• •12-lead electrocardiogram with pathologic abnormalities (this criterion does not apply to cohort 4)
• •Occupation in food handling industry, living with, or care of very young children (less than 5 years old), elderly (greater than 65 years), or immunocompromised (this criterion does not apply to cohort 4)
• •Having any known legal obligations, court appearances, professional meetings, vacations, planned events, or other reasons which might interfere with a person's availability for a 12-day inpatient stay. (this criterion does no apply to cohort 4)
• •Any other criteria which, in the investigator's opinion, would compromise the safety of the study, the ability of a subject to participate, or the results of the study